Stock 61Y MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Marinus Pharmaceuticals, Inc. BOERSE MUENCHEN

Equities

61Y

US56854Q2003

Market Closed - BOERSE MUENCHEN
Other stock markets
 15:43:23 2024-06-28 EDT 		5-day change 1st Jan Change
1.13 EUR -3.42% Intraday chart for Marinus Pharmaceuticals, Inc. -11.02% -88.64%
06-24 Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index CI
06-17 Sector Update: Health Care Stocks Decline Premarket Monday MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Decline Premarket Monday
MT
Top Premarket Decliners
MT
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study
MT
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus
CI
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
Sector Update: Health Care
MT
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent
MT
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program
CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M
MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024
CI
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial
CI
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket
MT
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours
MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q4 Revenue $7.2M, vs. Street Est of $8.1M
MT
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024
CI
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Marinus Pharmaceuticals Raises 2023 Product Revenue Expectation
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. 61Y Stock
  5. News Marinus Pharmaceuticals, Inc.
  6. Highlights